Dionna O Roberts1, Brittany Covert1, Mark J Rodeghier2, Nagina Parmar3, Michael R DeBaun1, Alexis A Thompson4, Robert I Liem4. 1. Department of Pediatrics, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN. 2. Rodeghier Consultants, Chicago, IL. 3. Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON. 4. Division of Hematology, Oncology & Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Department of Pediatrics, Northwestern University Feinberg School of Medicine.
Abstract
BACKGROUND: Few studies have investigated factors influencing participation rates for minority children with a chronic disease in clinical trials. The Silent Cerebral Infarct Multi-Center Clinical (SIT) Trial provides an opportunity to study the impact of demographic and socio-economic factors on randomization in a clinical trial among Black children. Our primary objective was to characterize the factors associated with successful randomization of children with sickle cell disease (SCD) and silent cerebral infarct (SCI) in the SIT Trial after initial consent. PROCEDURE: Differences in socio-economic and demographic variables, family history and disease-related variables were determined between eligible participants who were successfully randomized and those who were not randomized following initial consent. Head of household educational level and family income were examined separately for US versus non-US sites. RESULTS: Of 1,176 children enrolled in the SIT Trial, 1,016 (86%) completed screening. Of 208 (20%) children with qualifying SCI on pre-randomization MRI, 196 (94%) were successfully randomized. There were no differences in socio-economic, demographic, or disease-related variables between children who were or were not randomized. Participants from non-US sites were more likely to be randomized (22% vs. 12%, P = 0.011); although, randomization by country was associated with neither head of household education nor family income. CONCLUSION: In the SIT Trial, acceptance of random allocation was not associated with socio-economic or demographic factors. Although these factors may represent barriers for some participants, they should not bias investigators caring for children with SCD in their approach to recruitment for clinical trial participation.
RCT Entities:
BACKGROUND: Few studies have investigated factors influencing participation rates for minority children with a chronic disease in clinical trials. The Silent Cerebral Infarct Multi-Center Clinical (SIT) Trial provides an opportunity to study the impact of demographic and socio-economic factors on randomization in a clinical trial among Black children. Our primary objective was to characterize the factors associated with successful randomization of children with sickle cell disease (SCD) and silent cerebral infarct (SCI) in the SIT Trial after initial consent. PROCEDURE: Differences in socio-economic and demographic variables, family history and disease-related variables were determined between eligible participants who were successfully randomized and those who were not randomized following initial consent. Head of household educational level and family income were examined separately for US versus non-US sites. RESULTS: Of 1,176 children enrolled in the SIT Trial, 1,016 (86%) completed screening. Of 208 (20%) children with qualifying SCI on pre-randomization MRI, 196 (94%) were successfully randomized. There were no differences in socio-economic, demographic, or disease-related variables between children who were or were not randomized. Participants from non-US sites were more likely to be randomized (22% vs. 12%, P = 0.011); although, randomization by country was associated with neither head of household education nor family income. CONCLUSION: In the SIT Trial, acceptance of random allocation was not associated with socio-economic or demographic factors. Although these factors may represent barriers for some participants, they should not bias investigators caring for children with SCD in their approach to recruitment for clinical trial participation.
Authors: Addisalem Arega; Nancy J O Birkmeyer; Jon D N Lurie; Tor Tosteson; Jennifer Gibson; Brett A Taylor; Tamara Shawver Morgan; James N Weinstein Journal: Spine (Phila Pa 1976) Date: 2006-09-01 Impact factor: 3.468
Authors: Desiree Rivers; Euna M August; Ivana Sehovic; B Lee Green; Gwendolyn P Quinn Journal: Contemp Clin Trials Date: 2013-04-01 Impact factor: 2.226
Authors: Maria Montanaro; Raffaella Colombatti; Marisa Pugliese; Camilla Migliozzi; Fabiana Zani; Maria Elena Guerzoni; Sheila Manoli; Renzo Manara; Giorgio Meneghetti; Patrizia Rampazzo; Francesca Cavalleri; Marco Giordan; Paolo Paolucci; Giuseppe Basso; Giovanni Palazzi; Laura Sainati Journal: Ital J Pediatr Date: 2013-06-04 Impact factor: 2.638
Authors: Evelyn M Stevens; Chavis A Patterson; Yimei B Li; Kim Smith-Whitley; Lamia P Barakat Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: Lori C Jordan; Dionna O Roberts Williams; Mark J Rodeghier; Brittany V Covert Greene; Maria R Ponisio; James F Casella; Robert C McKinstry; Michael J Noetzel; Fenella J Kirkham; Emily R Meier; Beng Fuh; Melissa McNaull; Sharada Sarnaik; Suvankar Majumdar; Timothy L McCavit; Michael R DeBaun Journal: Am J Hematol Date: 2018-03-30 Impact factor: 10.047